ASCL.F Overzicht aandelen Ascletis Pharma Inc. is een biotechnologiebedrijf dat zich bezighoudt met onderzoek en ontwikkeling, productie, marketing en verkoop van farmaceutische producten op het Chinese vasteland. Meer informatie
Risicoanalyse Alle risicocontroles bekijken Leg je gedachten, links en bedrijfsverhaal vast
Ascletis Pharma Inc. Concurrenten Prijsgeschiedenis en prestaties
Overzicht van hoogtepunten, dieptepunten en veranderingen in de aandelenkoersen voor Ascletis Pharma Historische aandelenkoersen Huidige aandelenkoers HK$0.24 52 Week Hoogtepunt HK$0.25 52 Week Laag HK$0.14 Bèta 0.58 1 maand verandering 0% 3 maanden verandering 29.35% 1 Jaar Verandering -3.90% 3 jaar verandering -60.11% 5 jaar verandering -63.18% Verandering sinds IPO -60.12%
Recent nieuws en updates
Ascletis Announces Positive Results from U.S. Single Ascending Dose Study of Small Molecule Oral Gp-1R Agonist ASC30 Jan 21
Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily Oral Tablet for Treatment of Acne Nov 13
Update on Legal Proceedings Involving Ascletis Pharma Inc.'s ASC41 and ASC43F Oct 07
Ascletis Pharma Inc. Enters the Obesity Drug Space with Announcement of Two Ongoing U.S. Phase I Clinical Trials Utilizing Its Small Molecule GLP-1R Agonist ASC30 for Both Once-Monthly Subcutaneous Injection and Once-Daily Oral Tablet for the Treatment of Obesity Sep 17
Ascletis Pharma Inc. to Report Q2, 2024 Results on Aug 30, 2024 Jul 30
Ascletis Pharma Inc. Announces Presentation Designing Positive Interim 12-Week Results from Phase II Clinical Trial of ASC41 in Patients with Biopsy- Confirmed Mash At EASL Congress 2024 Jun 13 Meer updates bekijken
Ascletis Announces Positive Results from U.S. Single Ascending Dose Study of Small Molecule Oral Gp-1R Agonist ASC30 Jan 21
Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily Oral Tablet for Treatment of Acne Nov 13
Update on Legal Proceedings Involving Ascletis Pharma Inc.'s ASC41 and ASC43F Oct 07
Ascletis Pharma Inc. Enters the Obesity Drug Space with Announcement of Two Ongoing U.S. Phase I Clinical Trials Utilizing Its Small Molecule GLP-1R Agonist ASC30 for Both Once-Monthly Subcutaneous Injection and Once-Daily Oral Tablet for the Treatment of Obesity Sep 17
Ascletis Pharma Inc. to Report Q2, 2024 Results on Aug 30, 2024 Jul 30
Ascletis Pharma Inc. Announces Presentation Designing Positive Interim 12-Week Results from Phase II Clinical Trial of ASC41 in Patients with Biopsy- Confirmed Mash At EASL Congress 2024 Jun 13
Ascletis Pharma Inc., Annual General Meeting, May 23, 2024 Apr 28
Ascletis Pharma Inc. Announces Strategic Decisions on FXR Agonist ASC42 Apr 03
Ascletis Pharma Inc. Announces Poster Presentation of Phase II Study Final Results of FASN Inhibitor ASC40 for Treatment of Acne at 2024 AAD Annual Meeting Mar 11
Ascletis Pharma Inc. to Report Fiscal Year 2023 Results on Mar 25, 2024 Feb 24
Ascletis Pharma Inc. Announces Dosing of the First Patient in Phase III Clinical Trial of Asc40 (Denifanstat) for Treatment of Acne Jan 24
Ascletis Pharma Inc. Announces Positive Interim Results from 52-Week Phase Ii Clinical Trial of Once-Daily Asc41 Tablet in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis Jan 02
Ascletis Pharma Inc. Announces Initiation of Phase III Clinical Trial of ASC40 (Denifanstat) for Treatment of Acne Dec 05
Ascletis Pharma Inc. Announces Positive Interim Data from the Phase IIb Expansion Cohort of ASC22 (Envafolimab) for Chronic Hepatitis B Functional Cure Sep 29
Ascletis Pharma Inc. Announces Completion of Enrollment of 120 Patients in the Phase Ii Clinical Trial of FASN Inhibitor ASC40 Combined with Bevacizumab for Treatment of Recurrent Glioblastoma Sep 27
Ascletis Pharma Inc. to Report Q2, 2023 Results on Aug 21, 2023 Jul 24
Ascletis Pharma Inc. Announces Completion of Patient Enrollment for Phase Ii Clinical Trial of Asc42, an Fxr Agonist, for Primary Biliary Cholangitis Jul 22
Ascletis Pharma Inc., Annual General Meeting, Jun 29, 2023 Jun 06
Ascletis Pharma Inc. Announces China NMPA Approval of Conducting a Phase IIa Clinical Trial for ASC10 to Treat Respiratory Syncytial Virus Infection May 09
Ascletis Pharma Inc. Announces Oral Presentation at APASL Annual Meeting 2023 Demonstrates ASC22, a Subcutaneous PD-L1 Antibody, Can Achieve Functional Cure of Chronic Hepatitis B Feb 17
Ascletis Pharma Announces U.S. FDA Approval of Conducting Phase IIA Clinical Trial for ASC10 to Treat Respiratory Syncytial Virus Infection Feb 01
Ascletis Announces IND Approval of Oral Viral Polymerase Inhibitor ASC10 for Monkeypox Indication by China Nmpa Jan 27
Ascletis Pharma Inc. Doses 4 Healthy Subjects of the First Cohort in Multiple-Dose Escalation Phase I Clinical Trial of Oral 3CLpro Inhibitor ASC11 for COVID-19 Jan 17
Viking Therapeutics, Inc. Files Complaints Against Ascletis Pharma Inc Jan 03
Ascletis Announces Positive Phase I Clinical Results of Oral Rdrp Inhibitor Asc10 for Covid-19 Dec 13
Ascletis Pharma Inc. Announces IND Approval of Oral 3CLpro Inhibitor ASC11 for COVID-19 by China NMPA Dec 08
Ascletis Announces Completion of 180 Patient Enrollment for Phase II Clinical Trial of FASN Inhibitor Asc40 for Acne Dec 02
Ascletis Pharma Inc. Announces IND Filing of Oral 3CLpro Inhibitor ASC11 for COVID-19 Accepted by China NMPA Nov 30
Ascletis Announces IND Approval of Oral 3CLpro Inhibitor ASC11 for Covid-19 by U.S. FDA Nov 24
Ascletis Pharma Inc. Announces IND Approval of Oral PD-L1 Small Molecule Inhibitor ASC61 for Treatment of Advanced Solid Tumors by China NMPA Nov 18
Ascletis Pharma Inc. Announces IND Approval of Viral Polymerase Inhibitor ASC10 for Monkeypox Indication by U.S. FDA Nov 16
Ascletis Pharma Inc. Announces Poster Presentation of Phase I, Single-Dose Study of ASC43F for NASH at AASLD Annual Meeting 2022 Nov 07
Ascletis Announces U.S. IND Filing of Oral 3CLpro Inhibitor ASC11 for COVID-19 Nov 03
Ascletis Pharma Inc. Announces U.S. IND Filing of Oral Antiviral ASC10 for Monkeypox Indication Oct 27
Ascletis Announces Dosing of 24 Healthy Subjects of the First 3 Cohorts in Multiple-Dose Escalation Phase I Clinical Trial of Oral RdRp Inhibitor ASC10 for COVID-19 Oct 11
Ascletis Pharma Inc. Announces Dosing of the First Patient in Phase Ii Clinical Trial of Thrß Agonist Asc41 for 52-Week Treatment of Liver Biopsy-Proven Nash Oct 06
Ascletis Announces Dosing of the First Patient in the Phase IIb Expansion Cohort of ASC22 (Envafolimab) for Chronic Hepatitis B Functional Cure Sep 28
Ascletis Pharma Inc. Announces Clinical Study of PD-L1 antibody ASC22 Sep 16
Ascletis Pharma Inc. Announces Change of Company Secretary Aug 23
Ascletis Announces IND Approval of Oral RdRp Inhibitor ASC10 for COVID-19 by China NMPA Aug 22
Vascletis Pharma Inc. Announces First Subject Dosed in the U.S. Drug-Drug Interaction Study of FXR Agonist ASC42 for Treatment of Primary Biliary Cholangitis Aug 17
Ascletis Announces First Patient Dosed in the U.S. Phase I Clinical Trial of Oral PD-L1 Small Molecule Inhibitor Prodrug ASC61 for Treatment of Advanced Solid Tumors Aug 08
Ascletis Announces IND Filing of Oral RdRp Inhibitor ASC10 for COVID-19 Accepted by China NMPA Aug 05
Ascletis Announces FDA Clearance of Oral RdRp Inhibitor ASC10 to Conduct a Randomized, Placebo Controlled Phase Ib Study in Mild-to-Moderate COVID-19 Patients Aug 04
Ascletis Pharma Inc. to Report First Half, 2022 Results on Aug 22, 2022 Jul 28
Ascletis Announces U.S. IND Filing of Oral RdRp Inhibitor Drug Candidate ASC10 for COVID-19 Jul 07
Ascletis Pharma Inc. Announces Shanghai Public Health Clinical Center Completed the First Patient Dosing in Clinical Study of PD-L1 Antibody ASC22 in Combination with Chidamide for Functional Cure of HIV Infection Jul 05
Ascletis Pharma Inc. Announces First Subject Dosed in the Phase II Clinical Trial of ASC22 (Envafolimab) for Immune Restoration/ Functional Cure of HIV-1 Infection Jun 29
Ascletis Pharma Inc. Announces the Latest Phase Iib Clinical Trial Results of Subcutaneous Pd-L1 Antibody Asc22 (Envafolimab) in Patients with Chronic Hepatitis B (Chb) At an Oral Parallel Session of the International Liver Congress™ 2022 Jun 28
Ascletis Pharma Inc. Announces Oral Presentation on Updates from Phase IIb Clinical Trial of ASC22, a Subcutaneous PD-L1 Antibody for Functional Cure of Chronic Hepatitis B at EASL ILC 2022 Jun 16
Ascletis Pharma Inc. Appoints John P. Gargiulo as Chief Business Officer Jun 13
Ascletis Pharma Inc., Annual General Meeting, Jun 16, 2022 May 25 Ascletis Pharma Inc. Announces Approval of Investigational New Drug Application
Ascletis Pharma Inc. Announces 3CLpro Inhibitor ASC11 Demonstrated Potential to be Effective Treatment for COVID-19 Apr 20
Ascletis Pharma Inc. Receives Approval for Investigational New Drug Application by China National Medical Products Administration Apr 07
Ascletis Pharma Inc. Completes Patient Enrollment in Phase II Clinical Trial of ASC42 for Chronic Hepatitis B Indication Mar 31
Ascletis Pharma Inc. Announces the Latest Results of Preclinical Studies of Two Novel Anti-Cancer Drug Candidates,ASC61 and ASC60, to Be Presented At AACR Annual Meeting 2022 Mar 28
Ascletis Pharma Inc. to Report Fiscal Year 2021 Results on Mar 21, 2022 Mar 04
Ascletis Pharma Inc. Provides Earnings Guidance for the Year Ended December 31, 2021 Mar 01
Ascletis Pharma Inc. Provides Earnings Guidance for the Year Ended December 31, 2021 Feb 28
Ascletis Pharma Inc Announces Shanghai Public Health Clinical Center Initiated Functional Cure Study of Anti-PD-L1 Antibody ASC22 (Envafolimab) in Combination With Chidamide in HIV-Infected Patients Feb 15
Ascletis Pharma Inc. Announces Positive Data of Oral Double Prodrug ASC10 and Its Antiviral Nucleoside Analog ASC10-A Against Omicron Variant Feb 08
Ascletis Announces U.S. IND Approval of Oral PD-L1 Small Molecule Inhibitor ASC61 for Treatment of Advanced Solid Tumors Feb 07
Ascletis Pharma Inc. Announces IND Filing of Its Second FASN Inhibitor ASC60 for Advanced Solid Tumors Accepted by China NMPA Jan 27
Ascletis Pharma Inc. Announces First Patient Dosed in the Phase III Clinical Trial of FASN Inhibitor ASC40 Combined with Bevacizumab for Treatment of Recurrent Glioblastoma Jan 24
Ascletis Pharma Inc. Announces U.S. Ind Approval of Asc22, A Subcutaneously Administered Pd-L1 Antibody for Functional Cure of Chronic Hepatitis B Jan 18
Ascletis Pharma Inc. Announces First Patient Dosed in the Phase II Clinical Trial of FASN Inhibitor ASC40 for Treatment of Moderate to Severe Acne Jan 14
Ascletis Pharma Inc. Announces First Patient Dosed in the Phase II Clinical Trial of ASC42, An In-House Developed, Best-in-Class FXR Agonist for Chronic Hepatitis B Indication Jan 11
Ascletis Announces U.S. IND Filing for In-House Developed Oral PD-L1 Small Molecule Inhibitor ASC61 for Treatment of Advanced Solid Tumors Jan 10
Gannex Announces Completion of the U.S. Phase I Trial of ASC43F Jan 04
Ascletis Pharma Inc. Expands Ritonavir Oral Tablet Production and Announces Oral Direct-Acting Antiviral Pipeline Against SARS-COV-2 Virus Jan 03
Ascletis Pharma Inc. Announces Inclusion in New Catalogue of China National Reimbursement Drug List (NRDL) of ASCLEVIR®/ GANOVO® Regimen, an All-Oral Direct Anti-Hcv Therapy Dec 03
Ascletis Pharma Inc Announces Positive Topline Results from the U.S. Phase I Trial of Drug-Drug Interactions in Healthy Subjects and Pharmacokinetics in Patients with NAFLD for Its THRß Agonist ASC41 Sep 08
Ascletis Pharma Inc. Announces Completion of the Bridging Study and Initiation of Phase II Trial of FXR Agonist Asc42 in China for Chronic Hepatitis B Indication Aug 25
Ascletis Pharma Inc.'s artner Sagimet Dosed First Patient in FASCINATE-2 Phase IIb Trial in NASH Patients with Moderate to Advanced Fibrosis Aug 17
Ascletis Pharma Inc. Announces China NMPA Approves Phase II Clinical Trial of Asc40 for the Treatment of Patients with Acne Aug 09
China NMPA Approves Ascletis Pharma Inc.'s Phase III Clinical Trial of ASC40 Combined with Bevacizumab for Treatment of Patients with Recurrent Glioblastoma Jul 23
Ascletis Announces Dosing of the First Cohort of Healthy Subjects in the FXR Agonist ASC42 Bridging Study for Chronic Hepatitis B Indication in China Jul 14
Ascletis Pharma Inc. Receives China IND Approval of its FXR Agonist ASC42 for Chronic Hepatitis B Indication Jun 08
Gannex, a Wholly Owned Company of Ascletis Pharma Inc. Receives China IND Approval of Its FXR Agonist ASC42 for NASH Indication May 27
Ascletis Pharma Announces Clinical Trial Application of ASC40 Combined with Bevacizumab to Treat Patients with Recurrent Glioblastoma Accepted by China NMPA May 25
Ascletis Pharma Inc. Announces Positive Phase IIa HBV Results on Subcutaneously Administered PD-L1 Antibody ASC22 (Envafolimab) May 05
Ascletis Pharma Inc. to Report Fiscal Year 2020 Results on Mar 29, 2021 Mar 18
Gannex Announces U.S. IND Approval and Initiation of Global Development of THR-ß Agonist ASC41 for NASH Feb 26
Gannex Announces Positive Phase I Clinical Results on Its THR-ß Agonist ASC41 Jan 12
Ascletis Pharma Inc. Announces First Subject Dose with Gannex Pharma Co., Ltd.'s FXR Agonist Asc42 in U.S. Phase I Trial Dec 29
Ascletis Pharma Inc. Announces Subcutaneously PD-L1 Antibody ASC22 (Envafolimab) is Safe and Well Tolerated in Phase IIa HBV Study Dec 04
Ascletis Pharma Inc. Announces ASC40 (TVB-2640) Phase II Nash Trial Completed Patient Enrollment in China Nov 20
Ascletis Pharma Inc. Announces Approval for Its Nash Drug Candidate ASC42 Oct 13
Ascletis Pharma Inc. to Report First Half, 2020 Results on Aug 28, 2020 Aug 11 Rendement voor aandeelhouders ASCL.F US Biotechs US Markt 7D 0% 1.3% -0.3% 1Y -3.9% -2.3% 22.7%
Bekijk het volledige aandeelhoudersrendement
Rendement versus industrie: ASCL.F presteerde slechter dan de US Biotechs -sector, die het afgelopen jaar een rendement van -2.3 % opleverde.
Rendement versus markt: ASCL.F presteerde slechter dan US Market , dat het afgelopen jaar een rendement van 22.7 % opleverde.
Prijsvolatiliteit Is ASCL.F's price volatile compared to industry and market? ASCL.F volatility ASCL.F Average Weekly Movement n/a Biotechs Industry Average Movement 11.3% Market Average Movement 6.4% 10% most volatile stocks in US Market 18.8% 10% least volatile stocks in US Market 3.2%
Stabiele aandelenkoers: De aandelenkoers van ASCL.F is de afgelopen 3 maanden volatiel geweest in vergelijking met de US markt.
Volatiliteit in de loop van de tijd: Onvoldoende gegevens om de volatiliteitsverandering van ASCL.F in het afgelopen jaar te bepalen.
Over het bedrijf Ascletis Pharma Inc., een biotechnologiebedrijf, houdt zich bezig met onderzoek en ontwikkeling, productie, marketing en verkoop van farmaceutische producten op het Chinese vasteland. Het bedrijf biedt een Ritonavir-tablet en ASCLEVIR en GANOVO voor de behandeling van het hepatitis C-virus. Het ontwikkelt ook ASC22 voor de behandeling van CHB en HIV functionele genezing; ASC10 voor respiratoir syncytievirus; ASC10 en ASC11 voor de behandeling van COVID-19; ASC40, ASC41, ASC42, ASC43F FDC voor niet-alcoholische steatohepatitis; en ASC42 voor de behandeling van primaire biliaire cholangitis.
Meer tonen Ascletis Pharma Inc. Samenvatting Hoe verhouden de winst en inkomsten van Ascletis Pharma zich tot de beurswaarde? ASCL.F fundamentele statistieken Marktkapitalisatie US$494.79m Inkomsten(TTM ) -US$35.66m Inkomsten(TTM ) US$1.39m
355.4x P/S-verhouding
-13.9x Koers/Winstverhouding Inkomsten en omzet Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM) ASCL.F resultatenrekening (TTM ) Inkomsten CN¥10.09m Kosten van inkomsten CN¥22.72m Brutowinst -CN¥12.63m Overige uitgaven CN¥245.84m Inkomsten -CN¥258.47m
Laatst gerapporteerde inkomsten
Jun 30, 2024
Volgende inkomensdatum
n.v.t.
Winst per aandeel (EPS) -0.27 Brutomarge -125.17% Nettowinstmarge -2,561.68% Schuld/Eigen Vermogen Verhouding 0%
Hoe presteerde ASCL.F op de lange termijn?
Bekijk historische prestaties en vergelijking
Bedrijfsanalyse en status van financiële gegevens Gegevens Laatst bijgewerkt (UTC-tijd) Bedrijfsanalyse 2025/02/04 06:47 Aandelenkoers aan het einde van de dag 2024/12/16 00:00 Inkomsten 2024/06/30 Jaarlijkse inkomsten 2023/12/31
Gegevensbronnen De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC . De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
Pakket Gegevens Tijdframe Voorbeeld Amerikaanse bron * Financiële gegevens bedrijf 10 jaar Resultatenrekening Kasstroomoverzicht Balans Consensus schattingen analisten +3 jaar Financiële prognoses Koersdoelen analisten Marktprijzen 30 jaar Aandelenprijzen Dividenden, splitsingen en acties Eigendom 10 jaar Top aandeelhouders Handel met voorkennis Beheer 10 jaar Leiderschapsteam Raad van bestuur Belangrijkste ontwikkelingen 10 jaar
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie .
Analysemodel en Snowflake Details van het analysemodel dat is gebruikt om dit rapport te genereren, zijn beschikbaar op onze Github-pagina . We hebben ook handleidingen voor het gebruik van onze rapporten en tutorials op Youtube .
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github .
Bronnen van analisten Ascletis Pharma Inc. wordt gevolgd door 6 analisten. 2 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
Analist Instelling Ling Zhang China Merchants Securities (HK) Co., Ltd Mingrui Wang Everbright Securities Co. Ltd. Siao Ye Everbright Securities Co. Ltd.
Toon 3 meer analisten 
